The predictive role of serum <scp>hCG</scp> 0–4 days after methotrexate treatment for ectopic pregnancy is yet to be determined

Rottenstreich, Amihai

doi:10.1002/ijgo.12633

Cited by 5 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This difference could also represent a selection preference to treat these women surgically, as it is well established that higher serum βhCG levels and gestational sac measurements are associated with methotrexate treatment failure. 13,14 Time from EP to live birth delivery in the second pregnancy was 91 days longer in the methotrexate group (P = 0.070). This corresponds with the general recommendation to postpone pregnancy following methotrexate systemic treatment to reduce potential risk of teratogenicity.…”

Section: Discussionmentioning

confidence: 96%

“…Median EP gestational sac measurement and βhCG serum levels were also higher in the salpingectomy group. This difference could also represent a selection preference to treat these women surgically, as it is well established that higher serum βhCG levels and gestational sac measurements are associated with methotrexate treatment failure 13,14 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ectopic first pregnancy treated by methotrexate versus salpingectomy—Maternal and perinatal outcomes in a subsequent pregnancy: A retrospective study

Ohayon

Weissbach

Burke

et al. 2022

Intl J Gynecology & Obste

Self Cite

View full text Add to dashboard Cite

Objective To study obstetric outcomes of a second pregnancy among women with a first ectopic pregnancy (EP) treated with methotrexate compared with laparoscopic salpingectomy. Methods A retrospective cohort study including all women with a first EP and a following pregnancy that concluded by delivery at ≥24 weeks of gestation between March 2011 and April 2021. Second pregnancy outcomes were compared between women treated with methotrexate and those treated with salpingectomy in their first pregnancy. Results Overall, 125 women were included, of which 64 (51.2%) were treated with methotrexate and 61 (48.8%) were treated with salpingectomy. In women treated with salpingectomy, the proportion of women conceiving by in vitro fertilization and those with measured gestational sac diameter or β‐subunit human chorionic gonadotropin was higher. The proportion of women conceiving by in vitro fertilization in their second pregnancy was higher in the salpingectomy group (55.2% versus 18.0%, P < 0.001). All maternal and neonatal outcomes were similar in both groups. The rate of low birth weight < 2500 g was 7.8% in the methotrexate group versus 18% in the salpingectomy group (P = 0.111). Conclusion Maternal and neonatal outcomes of a second pregnancy among women treated for EP in their first pregnancy are similar in women treated by methotrexate and those treated by salpingectomy.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%